FDA Approves Lytenava for Wet AMD: A Step Forward for Retina Care

FDA Approves Lytenava for Wet AMD: A Step Forward for Retina Care

For individuals and families navigating the challenges of inherited retinal diseases (IRDs), advancements in eye care are always a source of hope. While Lytenava, a newly FDA-approved drug, specifically targets wet age-related macular degeneration (AMD), its approval marks a significant milestone in retinal disease treatment. This development underscores the ongoing commitment to addressing vision loss and can pave the way for further research and improved therapies that may eventually benefit the broader IRD community.

Outlook Therapeutics has successfully secured U.S. Food and Drug Administration (FDA) approval for Lytenava (bevacizumab) for the treatment of wet AMD. This approval comes after a prolonged regulatory journey, including three complete response letters (CRLs) from the FDA in 2023 and 2025. The company had to address concerns regarding a lack of substantial evidence of effectiveness. Following a formal dispute resolution request in April, the FDA's Office of New Drugs ruled that collective results from Outlook's NORSE TWO and NORSE EIGHT studies, along with supplemental information, were sufficient.

Lytenava is a novel formulation of the VEGF inhibitor bevacizumab and is the first version of this drug specifically approved for use in wet AMD. Wet AMD is a chronic, progressive retinal disease and a leading cause of severe vision loss globally, particularly among older adults. While compounded bevacizumab formulations have been used off-label for wet AMD, their reference product (Roche's Avastin/MabThera) is indicated only for cancer conditions. With Lytenava, ophthalmologists now have an FDA-approved, purpose-built ophthalmic option.

According to Outlook's chief executive, Bob Jahr, bevacizumab has been widely utilized in retina care for over two decades, despite the absence of an FDA-approved ophthalmic formulation. He stated that Lytenava